Lung Cancer: Diagnosis and Targeted Therapies

Dear Colleagues,

In the past decade, there have been incredible advances in the field of molecular oncology that have improved clinical management of lung cancer and outcome. Despite this, the drug therapy cure rate at the advanced stage for lung cancers remains low, necessitating the development of further innovative therapeutic strategies. Recent advances in sequencing technology, notably the introduction of next-generation sequencing, have enabled rapid, efficient, low-cost, and precise sequencing. Furthermore, extensive application of these latest technologies to basic cancer research has facilitated the in-depth molecular characterization of lung cancer from various perspectives (oncogenesis, tumor phylogeny, diagnosis, progression, metastasis, treatment response, etc.) with higher precision than before.

This Special Issue aims to publish original research papers and review articles related to advances in basic research on the genomics of lung cancer. Particular focus will be given to research using sequencing data expected to contribute to the development of novel cancer diagnostics and treatment techniques (including gene therapies) as well as new medical devices and drugs, such as studies on circulating tumor DNA, fusion gene, intratumor heterogeneity, tumor mutation burden, and microbiome. Furthermore, papers discussing cancer cell responses to molecular targeted therapies based on single-cell sequencing data will also be considered.

Dr. Taichiro Goto
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• lung cancer
• sequencing
• fusion gene
• intratumor heterogeneity
• molecular-targeted therapy
• liquid biopsy
• (neo)adjuvant therapy
• tumor mutation burden
• microbiome
• single-cell sequencing